You can trust Panmure to connect you to the capital you need, when you need it.

Latest Transactions

Oct 2017
  • Mullin International ltd
  • Sale to Adecco
  • Financial Adviser

Not disclosed

Aug 2017
  • Phoenix Global Resources plc
  • Reverse Takeover
  • Joint Broker to Enlarged Entity

£1,200.0 million

Jul 2017
  • Animalcare Group plc
  • Reverse Takeover and Placing
  • Nominated Adviser, Lead Bookrunner and Broker

£32.7 million


Our people are the cornerstone of our
business. Get to know them.

Matthew Hansen

Non-Executive Director

Matt Hansen is Head of UK and Europe at Atlas Merchant Capital based in London. Prior to joining Atlas in 2015, Matt was a Managing Director and Partner at Cerberus European Capital where he was responsible for European private equity. He previously worked at Madison Dearborn Partners in Chicago and London and in the Investment Banking division of Bear Stearns.

Matt earned a Bachelor of Business Administration degree in Finance from the University of Texas at Austin and an MBA from both Columbia Business School and London Business School.

David Schamis

Non-Executive Director

David Schamis is a Founding Partner and Chairman of the Investment Committee at Atlas Merchant Capital based in New York. Previously, David was a Managing Director at JC Flowers and a member of the Investment Committee. He started his career at Salomon Smith Barney where he worked in the financial institutions group.

David earned a Bachelor of Arts degree in Economics from Yale University.

Ian Axe

Chief Executive

Ian has over 20 years of capital markets experience working in brokerage, banking and market infrastructure in Europe, the United States, Asia and Africa. He has held a number of senior executive positions including Group CEO of LCH.Clearnet, the world’s leading multinational clearing house.

Previous investment banking experience includes: at Barclays, Global Head of Equity Finance, Global Head of Operations, COO (EMEA) for both the investment bank and wealth management; and Group COO at ABSA Capital. Ian has both built and transformed investment banking businesses, including the Lehman integration, and divesture of Barclays Global Investors (BGI), while at Barclays.

Ian has spent the last two years investing in and advising FinTech companies and currently sits as a non-executive director on the boards of new market venture IPSX, the world’s first Commercial Real Estate exchange, and Squalker, an equity swap brokerage technology venture.

Timothy J. Kacani

Non-Executive Director

Tim Kacani is a Managing Director and Chief Operating Officer of Atlas Merchant Capital and is based in New York. Before joining Atlas, Mr. Kacani was the CFO of Lightyear Capital as well as holding roles at JP Morgan Partners as a Vice President of Investment Partnerships, Tax and Distributions and Brother International Corporation and KPMG.

Tim is a Certified Public Accountant and holds a Bachelor of Science degree in Accounting from the University of Scranton.

Dr Ataf Ahmed

Non-Executive Director

Dr. Ataf Ahmed is the global head of Asset Management for the QInvest group. He is responsible for launching and building the asset management division and is responsible for launching QMAP, QInvest’s award winning managed account fund platform. Prior to joining QInvest, he was a Director in the UBS Wealth Management Hedge Funds group in Zurich. He started his career in the Barclays Group and his last role was Head of Strategic Asset Allocation for Barclays Wealth in London. Ataf has PhD in Semiconductor Physics from the University of Cambridge and is CFA Charterholder.

+974 4405 6553

Andrew Adcock


Andrew is Chairman of Majedie Investments plc, JP Morgan European Investment Trust plc and Victory Park Specialty Lending Investments plc, all of which are investment companies.
Andrew is an independent non-Executive Director of Foxtons Group plc, where he chairs the remuneration committee, and a non-Executive Director of F&C Global Smaller Companies plc and Kleinwort Benson Bank Limited. He is Chair of The Samuel Courtauld Trust and also a Director of the Courtauld Institute of Art.
He was previously Managing Partner of Brompton Asset Management and, until 2009, served as Vice Chairman of Citigroup Corporate Finance. Prior to this Andrew was a partner at Lazard LLC. He has over 30 years’ experience in the City of London and was instrumental in the establishment of BZW as a major corporate broking franchise prior to the business being sold to CSFB (now Credit Suisse).

Committee membership:

  • Remuneration Committee
  • Audit, Risk & Compliance Committee
  • Nomination Committee (Chair)

Michael Katounas

Non-Executive Director

Michael is the Deputy CEO of QInvest.  Prior to joining QInvest in April 2013, Michael spent several years with Credit Suisse, latterly as Director, Investment Banking in Dubai.  He previously worked in ABN Amro’s London corporate finance business following roles at Shell Oil and Procter & Gamble.  He has a Masters Degree from London School of Economics and is a CFA Charter Holder.

Tamim Al-Kawari

Non-Executive Director

Tamim is the Chief Executive Officer of QInvest.  He previously served as QInvest’s Deputy CEO and, prior to joining QInvest, was Goldman Sachs Managing Director and Country Head for Qatar.


“The Panmure team did an excellent job throughout our recent fund raise.  We were impressed by their advisory and distribution capabilities, with strong institutional access both in the UK and US.”

We are thrilled to have been the first tech IPO post Brexit and are grateful to the excellent team at Panmure Gordon who guided us to such a positive outcome.

“We would like to thank the Panmure team for their hard work and dedication to achieve a positive result for Eland Oil & Gas on a very tight timetable. To be able to generate new institutional demand, upscale the fundraise and place the stock at a premium is testament to the strength of their resources offering.”

“Since appointment, Panmure’s commitment and willingness to understand the Company’s business and strategy has contributed to Allergy achieving its corporate goals and increasing shareholder value. Panmure’s execution of our two transactions has been first-class, connecting us with new institutional investors while effectively managing and supporting the existing shareholder base. The Healthcare team has demonstrated its extensive knowledge of the sector throughout.”

Hear From More Happy Clients